# Effect of Glucagon and Glucagon-like Peptide-1 Co-agonism on Cardiac Function and Metabolism in Overweight Participants with Type 2 Diabetes

> **NCT04307797** · PHASE4 · COMPLETED · sponsor: **Cambridge University Hospitals NHS Foundation Trust** · enrollment: 10 (actual)

## Conditions studied

- Type 2 Diabetes
- Obesity

## Interventions

- **DRUG:** 0.9% Sodium-chloride
- **DRUG:** Exenatide (50ng/min for 30 minutes loading followed by 25ng/min maintenance) and glucagon 12.5ng/kg/min
- **DRUG:** Glucagon 12.5ng/kg/min and 0.9% saline
- **DRUG:** 0.9% Sodium-chloride
- **DRUG:** Exenatide (50ng/min for 30 minutes loading followed by 25ng/min maintenance) and glucagon 12.5ng/kg/min
- **DRUG:** Glucagon 12.5ng/kg/min

## Key facts

- **NCT ID:** NCT04307797
- **Lead sponsor:** Cambridge University Hospitals NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-18
- **Primary completion:** 2022-10-07
- **Final completion:** 2022-10-07
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2024-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04307797

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04307797, "Effect of Glucagon and Glucagon-like Peptide-1 Co-agonism on Cardiac Function and Metabolism in Overweight Participants with Type 2 Diabetes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04307797. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*